Cellectar Biosciences, Inc. (CLRB)
NASDAQ$0.3067+0.01 (3.34%)
Market Cap
$13.81M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
394 of 924
Rank in Industry
231 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
CLRB Insider Trading Activity
CLRB Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $8,400 | 1 | 100 |
Sells | $0 | 0 | 0 |
Related Transactions
| Longcor Jarrod | Chief Operating Officer | 1 | $8,400 | 0 | $0 | $8,400 |
About Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company …
Insider Activity of Cellectar Biosciences, Inc.
Over the last 12 months, insiders at Cellectar Biosciences, Inc. have bought $8,400 and sold $0 worth of Cellectar Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Cellectar Biosciences, Inc. have bought $95,762 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Longcor Jarrod (Chief Operating Officer) — $8,400.
The last purchase of 30,000 shares for transaction amount of $8,400 was made by Longcor Jarrod (Chief Operating Officer) on 2025‑01‑10.
List of Insider Buy and Sell Transactions, Cellectar Biosciences, Inc.
| 2025-01-10 | Longcor Jarrod | Chief Operating Officer | 30,000 0.0723% | $0.28 | $8,400 | -0.12% | ||
| 2021-09-14 | Swirsky Douglas J | director | 25,000 0.0418% | $1.04 | $26,000 | -43.80% | ||
| 2021-09-03 | DRISCOLL FREDERICK W | director | 19,417 0.0328% | $1.04 | $20,244 | -42.72% | ||
| 2021-03-04 | CARUSO JAMES V | President and CEO | 5,100 0.0103% | $1.70 | $8,659 | -43.68% | ||
| 2020-12-28 | Longcor Jarrod | Chief Business Officer | 29,630 0.0975% | $1.35 | $40,001 | -41.79% | ||
| 2020-12-28 | CARUSO JAMES V | President and CEO | 37,037 0.1219% | $1.35 | $50,000 | -41.79% | ||
| 2020-12-28 | Elefant Dov | Chief Financial Officer | 7,407 0.0244% | $1.35 | $9,999 | -41.79% | ||
| 2020-06-05 | Longcor Jarrod | Chief Business Officer | 65,218 0.4749% | $1.15 | $74,675 | +26.32% | ||
| 2020-06-05 | CARUSO JAMES V | President and CEO | 21,740 0.1583% | $1.15 | $24,892 | +26.32% | ||
| 2020-06-05 | Elefant Dov | Chief Financial Officer | 4,348 0.0317% | $1.15 | $4,978 | +26.32% | ||
| 2020-06-04 | HILL STEPHEN A | director | 18,000 0.1236% | $1.08 | $19,438 | +25.88% | ||
| 2019-02-28 | Longcor Jarrod | Chief Business Officer | 100 0.0021% | $2.00 | $200 | +6.90% | ||
| 2018-11-30 | CARUSO JAMES V | President and CEO | 1,000 0.0345% | $2.28 | $2,282 | -4.93% | ||
| 2018-11-29 | Sale | HILL STEPHEN A | director | 992 0.0329% | $2.21 | $2,192 | -5.78% | |
| 2018-08-16 | Longcor Jarrod | Chief Business Officer | 500 0.0149% | $2.71 | $1,355 | -22.38% | ||
| 2018-03-13 | Sale | Longcor Jarrod | Chief Business Officer | 13,000 0.0783% | $1.18 | $15,397 | -76.50% | |
| 2018-03-12 | Sale | CARUSO JAMES V | President and CEO | 34,000 0.2018% | $1.20 | $40,705 | -77.08% | |
| 2017-11-14 | Sale | NEIS JOHN | director | 5,214 0.0315% | $1.49 | $7,791 | -27.89% | |
| 2016-11-29 | NEIS JOHN | director | 333,333 2.668% | $1.49 | $496,666 | +6.45% | ||
| 2016-10-31 | Sale | Hertzberg Richard | 21,000 0.1919% | $2.03 | $42,609 | -9.19% |
Total: 75
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| Longcor Jarrod | Chief Operating Officer | 83141 0.1804% | $24,909.04 | 5 | 1 | <0.0001% |
| MARXE AUSTIN W & GREENHOUSE DAVID M | 10 percent owner | 1142368 2.4791% | $342,253.45 | 4 | 0 | |
| NEIS JOHN | director | 626103 1.3587% | $187,580.46 | 3 | 1 | +9.32% |
| Hertzberg Richard | 280000 0.6076% | $83,888.00 | 12 | 1 | <0.0001% | |
| BERNS PAUL L | director | 117371 0.2547% | $35,164.35 | 1 | 0 | +12.2% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$8,900,811 | 57 | -24.79% | $14.9M | |
$383,884 | 32 | -25.10% | $12.83M | |
Cellectar Biosciences, Inc. (CLRB) | $4,368,362 | 28 | -22.35% | $13.81M |
$550,893 | 22 | -22.12% | $15.07M | |
$112,810,270 | 18 | -1.20% | $12.64M |
CLRB Institutional Investors: Active Positions
| Increased Positions | 17 | +43.59% | 1M | +9.69% |
| Decreased Positions | 15 | -38.46% | 10M | -73.04% |
| New Positions | 6 | New | 621,285 | New |
| Sold Out Positions | 10 | Sold Out | 10M | Sold Out |
| Total Postitions | 41 | +5.13% | 5M | -63.36% |
CLRB Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Vanguard Group Inc | $499.00 | 3.75% | 1.73M | +15 | +<0.01% | 2024-12-31 |
| Adar1 Capital Management, Llc | $169.00 | 1.27% | 585,261 | -436,900 | -42.74% | 2024-12-31 |
| Squarepoint Ops Llc | $150.00 | 1.13% | 520,240 | +520,240 | New | 2024-12-31 |
| Ubs Group Ag | $109.00 | 0.82% | 376,199 | +373,622 | +14,498.33% | 2024-12-31 |
| Geode Capital Management, Llc | $101.00 | 0.76% | 350,885 | -1,567 | -0.45% | 2024-12-31 |
| Blackrock, Inc. | $67.00 | 0.51% | 232,509 | +189 | +0.08% | 2024-12-31 |
| Altium Capital Management Llc | $62.00 | 0.47% | 215,000 | 0 | 0% | 2024-12-31 |
| Bank Of America Corp /De/ | $60.00 | 0.45% | 206,783 | +41,704 | +25.26% | 2024-12-31 |
| Jpmorgan Chase & Co | $53.00 | 0.4% | 182,403 | +159,234 | +687.27% | 2024-12-31 |
| Morgan Stanley | $52.00 | 0.39% | 178,719 | +39,488 | +28.36% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.